- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05114213
MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC (MASPAC)
MR-Guided Adaptive Stereotactic Body Radiotherapy (SBRT) of Primary Tumor for Pain Control in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - a Randomized, Controlled Clinical Study
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Patients not progressing after 8 weeks of standard of care systemic therapy (SoC-CT: minimum doublet chemotherapy) will be included and randomized between arm A, receiving MR-guided adaptive SBRT of the primary tumor combined with continuation of SoC-CT, and arm B, continuing SoC-CT without SBRT.
Arm A: The primary tumor is treated with SBRT (6.6 Gy x 5) on a MR-LINAC in breath-hold technique. This scheme was shown to have a reasonable toxicity profile on a conventional LINAC. A low toxicity profile is even more important in patients with metastatic and therefore definitively incurable cancer. Therefore, treatment is performed on a MR-LINAC to deliver high doses to the tumor while keeping the toxicity profile as low as possible. For this purpose, daily adaptive planning is performed aiming to maintain stringent dose constraints for organs at risk (duodenum / stomach / bowel / kidney). Chemotherapy will be continued after SBRT. Arm B: Continuing SoC-CT (according to clinical routine appr. 2 weeks after the previous cycle) without SBRT.
Type d'étude
Inscription (Anticipé)
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
- Nom: Georg Beyer, Dr.
- Numéro de téléphone: +4989440072391
- E-mail: Georg.Beyer@med.uni-muenchen.de
Sauvegarde des contacts de l'étude
- Nom: Ulrike Pflugradt
- E-mail: Ulrike.Pflugradt@med.uni-muenchen.de
Lieux d'étude
-
-
-
Heidelberg, Allemagne
- Pas encore de recrutement
- University Hospital of Heidelberg, Dep. of Radiation Oncology
-
Contact:
- Juliane Hörner-Rieber, PD Dr.
-
-
Bavaria
-
Munich, Bavaria, Allemagne, 81377
- Recrutement
- University of Munich, Dep. of Radiation Oncology
-
Chercheur principal:
- Maximilian Niyazi, MD, MSc
-
-
-
-
-
Zürich, Suisse
- Pas encore de recrutement
- University Hospital of Zurich
-
Contact:
- Matthias Guckenberger, Prof. Dr.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male and female patients with histologically proven, metastatic pancreatic adenocarcinoma of the pancreatic head or body amenable for MR-guided adaptive SBRT with at least stable disease after 8 weeks of standard of care doublet chemotherapy
- age >18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2
- Ability to follow study instructions and likely to attend and complete all required visits
Exclusion Criteria:
- Subjects not able to give consent
- Subjects without legal capacity who are unable to understand the nature, scope, significance and consequences of this clinical study
- Simultaneous participation in another clinical study or participation in any clinical trial involving an investigational medicinal product or treatment within 30 days prior to beginning of this study
- Subjects with a physical or psychiatric condition which at the investigator's discretion may put the subject at risk, may confound the study results, or may interfere with the subject's participation in this study
- Women of child bearing potential or sexually active males not willing to use effective contraception while on treatment and 12 weeks after the end of treatment (such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices) unless they are surgically sterilized / hysterectomized or there are any other criteria considered sufficiently reliable by the investigator in individual cases
- Biopsy proven tumor invasion into the stomach and/or duodenum
- Medically uncontrolled pain
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Arm A: SBRT
mPDAC patients not progressing after 8 weeks of standard of care systemic therapy (SoC-CT: minimum doublet chemotherapy).
The primary tumor is treated with SBRT (6.6Gy x 5) on a MR-LINAC in breath-hold technique.
For this purpose, daily adaptive planning is performed aiming to maintain stringent dose constraints for organs at risk (duodenum / stomach / bowel / kidney).
Chemotherapy will be continued after SBRT.
|
online adaptive MR-guided hypofractionated stereotactic radiotherapy
Autres noms:
The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
|
Comparateur actif: Arm B: SOC
Continuing SoC-CT (according to clinical routine appr. 2 weeks after the previous cycle) without SBRT.
|
The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Mean cumulative pain index
Délai: through study completion, at least 24 weeks or until death
|
Mean Cumulative pain index: AUC of pain scores rated every 4 weeks until death or end of study using numeric rating scale (NRS, 0= no pain, 10 = worst pain) divided by number of multiples of 4 weeks since randomization
|
through study completion, at least 24 weeks or until death
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Number of biliary complications
Délai: through study completion, at least 24 weeks or until death
|
Biliary complications defined as cholangitis or post-hepatic cholestasis requiring drainage
|
through study completion, at least 24 weeks or until death
|
Malnutrition
Délai: through study completion, at least 24 weeks or until death
|
Nutritional status measuring bioimpedance-derived phase angle (BIA) every 12 weeks
|
through study completion, at least 24 weeks or until death
|
Treatment toxicity
Délai: through study completion, at least 24 weeks or until death
|
Treatment toxicity according to CTCAE v5.0
|
through study completion, at least 24 weeks or until death
|
Death from any cause
Délai: through study completion
|
through study completion
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Maximilian Niyazi, Prof. Dr., Depatment of Radiation Oncology, University Hospital, LMU Munich
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 20-973
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur SBRT
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyComplétéCancer du poumonÉtats-Unis, Canada
-
Soonchunhyang University HospitalSMG-SNU Boramae Medical CenterPas encore de recrutementTumeurs | Tumeur maligne secondaire
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Actif, ne recrute pasCancer du pancréas | Adénocarcinome périampullaireÉtats-Unis
-
Duke UniversityGateway for Cancer ResearchActif, ne recrute pasCancer du seinÉtats-Unis
-
Sidney Kimmel Comprehensive Cancer Center at Johns...ComplétéSarcome | Maladie métastatique | Sites osseuxÉtats-Unis
-
European Organisation for Research and Treatment...Pas encore de recrutementCancer du sein | Cancer colorectal | NSCLC | Cancer de la prostate | Maladie oligométastatique
-
Istituto Clinico HumanitasPas encore de recrutement
-
Universitaire Ziekenhuizen KU LeuvenRecrutementCancer de la prostate | Radiothérapie | SBRTBelgique
-
Institute of Cancer Research, United KingdomRecrutementCancer de la prostateRoyaume-Uni
-
Centro Cardiologico MonzinoIstituto Europeo di OncologiaRecrutementTachycardie ventriculaire réfractaireItalie